Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters
Shariftabrizi A, Kothari S, George S, Attwood K, Levine E, Lamonica D. Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters. The Oncologist 2023, 28: 246-251. PMID: 36651837, PMCID: PMC10020806, DOI: 10.1093/oncolo/oyac245.Peer-Reviewed Original ResearchMeSH KeywordsBone and BonesBone NeoplasmsHumansMaleProstatic Neoplasms, Castration-ResistantRadiumRetrospective StudiesConceptsBaseline BSIBone scan indexMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerOverall survivalSkeletal metastasesRa-223 therapyRa-223 treatmentRadium-223 treatmentTreatment-associated reductionChemotherapy-naïve patientsMedian overall survivalAbsolute neutrophil countRadium-223 dichlorideHigh serum PSANovel treatment modalitiesAlkaline phosphatase levelsChemotherapy-naïveTreatment tolerabilityNeutrophil countSerum PSABone scanLaboratory parametersPatient selection